BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 19031473)

  • 1. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
    Kagan KO; Valencia C; Livanos P; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jan; 33(1):18-22. PubMed ID: 19031473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Maiz N; Valencia C; Kagan KO; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 May; 33(5):512-7. PubMed ID: 19338027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
    Kagan KO; Staboulidou I; Cruz J; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Nov; 36(5):542-7. PubMed ID: 20503223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β-hCG and PAPP-A: a 5-year prospective study.
    Ghaffari SR; Tahmasebpour AR; Jamal A; Hantoushzadeh S; Eslamian L; Marsoosi V; Fattahi F; Rajaei M; Niroomanesh S; Borna S; Beigi A; Khazardoost S; Saleh-Gargari S; Rahimi-Sharbaf F; Farrokhi B; Bayani N; Tehrani SE; Shahsavan K; Farzan S; Moossavi S; Ramezanzadeh F; Dastan J; Rafati M
    Ultrasound Obstet Gynecol; 2012 May; 39(5):528-34. PubMed ID: 21793085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective validation of first-trimester combined screening for trisomy 21.
    Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
    Kagan KO; Anderson JM; Anwandter G; Neksasova K; Nicolaides KH
    Prenat Diagn; 2008 Dec; 28(13):1209-13. PubMed ID: 19039823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
    Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuchal fold thickness, nasal bone absence or hypoplasia, ductus venosus reversed flow and tricuspid valve regurgitation in screening for trisomies 21, 18 and 13 in the early second trimester.
    Geipel A; Willruth A; Vieten J; Gembruch U; Berg C
    Ultrasound Obstet Gynecol; 2010 May; 35(5):535-9. PubMed ID: 20183867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-trimester screening for trisomies 18 and 13, triploidy and Turner syndrome by detailed early anomaly scan.
    Wagner P; Sonek J; Hoopmann M; Abele H; Kagan KO
    Ultrasound Obstet Gynecol; 2016 Oct; 48(4):446-451. PubMed ID: 26611869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome.
    Karadzov-Orlic N; Egic A; Milovanovic Z; Marinkovic M; Damnjanovic-Pazin B; Lukic R; Joksic I; Curkovic A; Mikovic Z
    Prenat Diagn; 2012 Jul; 32(7):638-43. PubMed ID: 22570267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.